Topical application of bleaching phenols; In-vivo studies and mechanism of action relevant to melanoma treatment

Melanoma Research

Volumn 21, Issue 2, 2011, Pages 115-126

  Hariharan, Vidhya ^a   Toole, Timothy ^b   Klarquist, Jared ^c   Mosenson, Jeffrey ^a   Longley, B Jack ^d   Le Poole, I Caroline ^a,c,e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c Oncology Institute   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4 tertiary butyl phenol; depigmentation; familial melanoma; monobenzyl ether of hydroquinone; tyrosinase related protein 1; tyrosinase related protein 2 tyrosinase

Indexed keywords

4 TERTIARY BUTYL PHENOL; BLEACHING AGENT; CYTOKINE; MONOBENZYL ETHER OF HYDROQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; DEPIGMENTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VIVO STUDY; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADMINISTRATION, TOPICAL; ANIMALS; BLEACHING AGENTS; CELL LINE, TUMOR; EPIDERMIS; HUMANS; LANGERHANS CELLS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOLS; SKIN NEOPLASMS;

EID: 79952993244     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328343f542     Document Type: Article

References (36)

1. Bolognia JL LK, Somma S. Depigmentation therapy. Dermatol Ther 2001;14:29-34. (Pubitemid 32246878)
2. Oliver EASL, Warren LH. Occupational leukoderma. Arch Dermatol Syphilol 1940;42:993-998.
3. Klauder JV, Hardy MK. Occupational leukoderma. Arch Dermatol Syphilol 1948;57:778-779.
4. Mosher DB, Parrish JA, Fitzpatrick TB. Mono-benzyl-ether of hydroquinoneretrospective study of treatment of 18 vitiligo patients and a review of literature. Br J Dermatol 1977;97:669-679.
5. Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, Le Poole IC. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol 2010;130:211-220.
6. Westerhof W, d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigm Cell Res 2007;20:345-359. (Pubitemid 47390114)
7. Manini P, Napolitano A, Westerhof W, Riley PA, d'Ischia M. A reactive orthoquinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem Res Toxicol 2009;22:1398-1405.
8. Manga P, Sheyn D, Yang F, Sarangarajan R, Boissy RE. A role for tyrosinase-related protein 1 in 4-tert-butyl phenol-induced toxicity in melanocytes-implications for vitiligo. Am J Pathol 2006;169:1652-1662. (Pubitemid 351181997)
9. Douat-Casassus C, Marchand-Geneste N, Diez E, Aznar C, Picard P, Geoffre S, et al. Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol Biosyst 2006;2:240-249. (Pubitemid 43970277)
10. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigm Cell Res 2003;16:254-260. (Pubitemid 36597065)
11. Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 2006;177:4168-4177. (Pubitemid 44359952)
12. van den Boorn JG, Konijnenberg D, Tjin EPM, Picavet DI, Meeuwenoord NJ, Filippov DV, et al. Effective melanoma immunotherapy in mice by the skindepigmenting agent monobenzone and the adjuvants imiquimod and CpG. Plos One 2010;5:e10626.
13. Hansson J. Familial melanoma. Surg Clin N Am 2008;88:897-916. (Pubitemid 352040751)
14. Le Poole C, van den Wijngaard R, Westerhof W, Dormans J, van den Berg FM, Verkruisen RP, et al. Organotypic culture of human skin to study melanocyte migration. Pigm Cell Res 1994;7:33-43.
15. Pistoor FHM, Rambukkana A, Kroezen M, Lepoittevin JP, Bos JD, Kapsenberg ML, Das PK. Novel predictive assay for contact allergens using human skin explant cultures. Am J Pathol 1996;149:337-343. (Pubitemid 26231004)
16. Rambukkana A, Pistoor FHM, Bos JD, Kapsenberg ML, Das PK. Effects of contact allergens on human langerhans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin-1 beta protein. Labor Invest 1996;74:422-436. (Pubitemid 26072084)
17. Kunisada T, Lu SZ, Yoshida H, Nishikawa S, Mizoguchi M, Hayashi S, et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 1998;187:1565-1573. (Pubitemid 28235098)
18. Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, Guevara-Patino JA, Le Poole IC. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Inves Dermatol 2008;128:2041-2048. (Pubitemid 352001226)
19. Le Poole C, van den Wijngaard R, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions-an immunohistochemical investigation. J Invest Dermatol 1993;100:816-822. (Pubitemid 23151246)
20. Boudreau J, Koshy S, Cummings D, Wan Y. Culture of myeloid dendritic cells from bone marrow precursors. J Vis Exp 2008; pii: 769.
21. Diamond JR, Borges VF, Eckhardt SG, Jimeno A. BRCA in breast cancer: from risk assessment to therapeutic prediction. Drug News Perspect 2009;22:603-608.
22. Panchal S, Bordeleau L, Poll A, Llacuachaqui M, Shachar O, Ainsworth P, et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet 2010;77:273-279.
23. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Develop 1997;11:2822-2834. (Pubitemid 27481683)
24. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin LD. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 2003;22:5055-5059. (Pubitemid 37026403)
25. Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer 1997;33:135-143. (Pubitemid 27099581)
26. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195. (Pubitemid 34773774)
27. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006;11:1709-1726. (Pubitemid 44371047)
28. Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmunol 2008;10:227-243.
29. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139-140.
30. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard R, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol 2004;9:68-72. (Pubitemid 38096202)
31. Gillet J-P, Gottesman MM. Mechanisms of Multidrug Resistance in Cancer. In: Zhou J, editor. Multi-drug resistance in cancer. New York: Springer; 2010. pp. 47-76.
32. Baguley BC. Multidrug resistance in cancer. In: Zhou J, editor. Multi-drug resistance in cancer. New York: Springer; 2010. pp. 1-14.
33. Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo. Dermatology 2002;204:194-201. (Pubitemid 34628308)
34. Nordlund JJ. Nonmelanoma skin cancer in vitiligo patients. J Am Acad Dermatol 2009;61:1080-1081.
35. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, et al. Melanoma-specific CD4 (+) T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-1971. (Pubitemid 26158888)
36. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 1997;14:173-192. (Pubitemid 27185947)